Trial · NCT02144077
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 52
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application site pain | General disorders | BF-200 ALA | 134 | 138 | 718 |
| other | Application site pain | General disorders | Methyl-aminolevulinate | 143 | 143 | 751 |
| other | Application site erythema | General disorders | BF-200 ALA | 120 | 138 | 309 |
| other | Application site erythema | General disorders | Methyl-aminolevulinate | 126 | 143 | 288 |
| other | Application site pruritus | General disorders | BF-200 ALA | 59 | 138 | 91 |
| other | Application site pruritus | General disorders | Methyl-aminolevulinate | 49 | 143 | 84 |
| other | Application site oedema | General disorders | BF-200 ALA | 42 | 138 | 86 |
| other | Application site oedema | General disorders | Methyl-aminolevulinate | 52 | 143 | 108 |
| other | Application site paraesthesia | General disorders | BF-200 ALA | 40 | 138 | 64 |
| other | Application site paraesthesia | General disorders | Methyl-aminolevulinate | 39 | 143 | 65 |
| other | Application site scab | General disorders | BF-200 ALA | 34 | 138 | 45 |
| other | Application site scab | General disorders | Methyl-aminolevulinate | 41 | 143 | 49 |
| other | Application site induration | General disorders | BF-200 ALA | 32 | 138 | 63 |
| other | Application site induration | General disorders | Methyl-aminolevulinate | 27 | 143 | 50 |
| other | Application site discharge | General disorders | BF-200 ALA | 24 | 138 | 38 |
| other | Application site discharge | General disorders | Methyl-aminolevulinate | 24 | 143 | 32 |
| other | Application site exfoliation | General disorders | BF-200 ALA | 22 | 138 | 25 |
| other | Application site exfoliation | General disorders | Methyl-aminolevulinate | 12 | 143 | 13 |
| other | Application site erosion | General disorders | BF-200 ALA | 18 | 138 | 22 |
| other | Application site erosion | General disorders | Methyl-aminolevulinate | 9 | 143 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02144077/events